{"component": "clause", "props": {"groups": [{"size": 2, "snippet": "(a) Clearside shall provide to Arctic Vision electronic copies of the documents relating to Licensed Products set forth on Exhibit B(i) hereto within [***] of Clearside\u2019s procurement or generation of such documents.\n(b) Clearside shall provide to Arctic Vision electronic copies of each of the documents set forth on Exhibit B(ii) hereto within [***] of Clearside\u2019s procurement or generation of such documents.\n(c) To the extent not included in Exhibit B(ii), Clearside shall also provide to Arctic Vision all additional data and documents Controlled by the Clearside Entities and relating to Licensed Products that are [***] for Arctic Vision to file IND(s) in the Territory, including Know-How, regulatory data, clinical data, [***] which Arctic Vision did not and could not reasonably Certain information has been excluded from this agreement (indicated by \u201c[***]\u201d) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. know of. Notwithstanding the foregoing, to the extent any data and documents are required by a Regulatory Authority in connection with Arctic Vision\u2019s filing of IND(s) or Drug Approval Application(s) in the Territory, Clearside shall (i) provide to Arctic Vision all such data and documents Controlled by the Clearside Entities [***] existing as of the Effective Date for the Licensed Products, and (ii) use Commercially Reasonable Efforts to provide to Arctic Vision all such data and documents Controlled by (A) [***] and (B) [***].\n(d) Throughout the Term, Clearside shall provide Arctic Vision with an update of any material regulatory developments (e.g., NDA filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Clearside, Clearside\u2019s Affiliates or licensees, and upon Arctic Vision\u2019s request, Clearside shall make available to Arctic Vision copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Clearside Entities or any of their sublicensees (collectively, the \u201cClearside Product Data\u201d), to the extent (i) such Clearside Product Data are [***] for any Arctic Vision Entity or their sublicensees to Develop, Manufacture or have Manufactured, or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement and are Controlled by the Clearside Entities, (ii) such Clearside Product Data are required by Regulatory Authority in the Territory in connection with the Development, Manufacturing, or Commercialization of Licensed Product in the Field in the Territory and are Controlled by the Clearside Entities or any of their Third Party sublicensees existing as of the Effective Date for the Licensed Products, and (iii) [***], such Clearside Product Data are required by Regulatory Authority in the Territory in connection with the Development, Manufacturing, or Commercialization of Licensed Product in the Field in the Territory and are Controlled by (A) [***] and (B) [***]; provided that (A) [***] and, [***], (B) [***], and (C) Clearside\u2019s grant of access or rights to Arctic Vision to any Clearside Product Data that are also Controlled by any Clearside sublicensee of a product other than the Licensed Products shall be conditioned upon Arctic Vision\u2019s payment of any amounts payable to such sublicensee in connection therewith. Clearside hereby grants to Arctic Vision and Arctic Vision\u2019s Affiliates or sublicensees a right to access, use and reference the Clearside Product Data and Clearside Regulatory Documents in any Regulatory Filing made by Arctic Vision (or its Affiliates or sublicensees as the case may be) related to Licensed Product during the Term in the Territory. Other than the activities set forth in this Section 2.02 (Technology Sharing), Clearside will not perform any obligations set forth in this Agreement until [***] without Clearside\u2019s written consent, not to be unreasonably withheld, conditioned or delayed.\n(e) Throughout the Term, upon Clearside\u2019s request, Arctic Vision shall make available to Clearside copies of Arctic Vision Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that pertain to Licensed Product and are Controlled by an Arctic Vision Entity or its sublicensee or sub-contractor (collectively, the \u201cArctic Vision Product Data\u201d), to the extent such Arctic Vision Product Data are [***] for Clearside, its Affiliates or (sub)licensees to exercise its retained rights. Arctic Vision hereby grants to Clearside and Clearside\u2019s Affiliates or sublicensees a right to access, use and reference the Arctic Vision Product Data and Arctic Vision Regulatory Documents in any Regulatory Filing made by Certain information has been excluded from this agreement (indicated by \u201c[***]\u201d) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. Clearside ([***]) pertaining to Licensed Product in connection with the exercise of its retained rights; provided that such grant of right to any of Clearside\u2019s sublicensees shall [***].", "snippet_links": [{"key": "the-documents", "type": "clause", "offset": [66, 79]}, {"key": "relating-to", "type": "definition", "offset": [80, 91]}, {"key": "licensed-products", "type": "clause", "offset": [92, 109]}, {"key": "to-the-extent", "type": "clause", "offset": [415, 428]}, {"key": "not-included", "type": "clause", "offset": [429, 441]}, {"key": "additional-data-and-documents", "type": "clause", "offset": [510, 539]}, {"key": "to-file", "type": "definition", "offset": [644, 651]}, {"key": "in-the-territory", "type": "clause", "offset": [659, 675]}, {"key": "regulatory-data", "type": "clause", "offset": [697, 712]}, {"key": "clinical-data", "type": "definition", "offset": [714, 727]}, {"key": "certain-information", "type": "clause", "offset": [788, 807]}, {"key": "such-information", "type": "definition", "offset": [877, 893]}, {"key": "not-material", "type": "clause", "offset": [901, 913]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [923, 975]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [986, 1015]}, {"key": "in-connection-with", "type": "clause", "offset": [1093, 1111]}, {"key": "drug-approval", "type": "definition", "offset": [1148, 1161]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [1320, 1344]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [1381, 1416]}, {"key": "to-provide", "type": "definition", "offset": [1417, 1427]}, {"key": "regulatory-developments", "type": "clause", "offset": [1606, 1629]}, {"key": "regulatory-approval", "type": "definition", "offset": [1687, 1706]}, {"key": "available-to", "type": "definition", "offset": [1850, 1862]}, {"key": "regulatory-documents", "type": "definition", "offset": [1887, 1907]}, {"key": "safety-and", "type": "clause", "offset": [1954, 1964]}, {"key": "pharmacovigilance-data", "type": "definition", "offset": [1965, 1987]}, {"key": "each-case", "type": "definition", "offset": [1992, 2001]}, {"key": "related-to", "type": "clause", "offset": [2011, 2021]}, {"key": "in-the-field", "type": "clause", "offset": [2039, 2051]}, {"key": "product-data", "type": "definition", "offset": [2152, 2164]}, {"key": "to-develop", "type": "definition", "offset": [2275, 2285]}, {"key": "have-manufactured", "type": "definition", "offset": [2302, 2319]}, {"key": "in-accordance-with", "type": "definition", "offset": [2385, 2403]}, {"key": "required-by-regulatory-authority", "type": "clause", "offset": [2502, 2534]}, {"key": "the-development", "type": "clause", "offset": [2571, 2586]}, {"key": "commercialization-of-licensed-product", "type": "clause", "offset": [2606, 2643]}, {"key": "third-party-sublicensees", "type": "clause", "offset": [2735, 2759]}, {"key": "provided-that", "type": "clause", "offset": [3089, 3102]}, {"key": "grant-of-access", "type": "clause", "offset": [3156, 3171]}, {"key": "be-conditioned", "type": "clause", "offset": [3335, 3349]}, {"key": "payment-of", "type": "definition", "offset": [3371, 3381]}, {"key": "payable-to", "type": "definition", "offset": [3394, 3404]}, {"key": "right-to-access", "type": "clause", "offset": [3537, 3552]}, {"key": "regulatory-filing", "type": "definition", "offset": [3641, 3658]}, {"key": "the-case", "type": "definition", "offset": [3719, 3727]}, {"key": "during-the-term", "type": "clause", "offset": [3764, 3779]}, {"key": "the-activities", "type": "clause", "offset": [3809, 3823]}, {"key": "in-this-agreement", "type": "clause", "offset": [3930, 3947]}, {"key": "written-consent", "type": "definition", "offset": [3980, 3995]}, {"key": "to-exercise", "type": "clause", "offset": [4562, 4573]}, {"key": "retained-rights", "type": "definition", "offset": [4578, 4593]}, {"key": "pertaining-to", "type": "definition", "offset": [5026, 5039]}, {"key": "exercise-of", "type": "clause", "offset": [5080, 5091]}, {"key": "grant-of-right-to", "type": "clause", "offset": [5132, 5149]}], "samples": [{"hash": "d92l7FetfRG", "uri": "/contracts/d92l7FetfRG#technology-sharing", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 31.3490759754, "published": true}], "hash": "e3b4b9ffa8993d738abbd7d97470bd70", "id": 3}, {"size": 2, "snippet": "Each of AL2, ReSound and Danavox will make available to the other parties the use of its respective Technology to perform its portions of the Development Program, will provide to the other parties, as soon as reasonably available, copies of the tangible aspects of such Technology including, without limitation, layout design vellums, specifications and other engineering documents, and, subject to the terms and conditions of this Agreement, will supply the personnel, facilities, and materials necessary to carry out its respective portion of the Development Program and to allow the manufacture, use and selling of the Products pursuant to the licenses granted under this Agreement. In particular, AL2 shall be responsible for providing the AL2 Technology, Danavox shall be responsible for providing the Danavox Technology and ReSound shall be responsible for providing the ReSound Technology.", "snippet_links": [{"key": "available-to", "type": "definition", "offset": [43, 55]}, {"key": "the-other-parties", "type": "clause", "offset": [56, 73]}, {"key": "the-development-program", "type": "clause", "offset": [138, 161]}, {"key": "will-provide", "type": "clause", "offset": [163, 175]}, {"key": "reasonably-available", "type": "definition", "offset": [209, 229]}, {"key": "copies-of-the", "type": "clause", "offset": [231, 244]}, {"key": "without-limitation", "type": "clause", "offset": [292, 310]}, {"key": "engineering-documents", "type": "definition", "offset": [360, 381]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [403, 441]}, {"key": "respective-portion", "type": "definition", "offset": [523, 541]}, {"key": "to-allow-the", "type": "clause", "offset": [573, 585]}, {"key": "the-products", "type": "clause", "offset": [618, 630]}, {"key": "licenses-granted", "type": "clause", "offset": [647, 663]}, {"key": "in-particular", "type": "clause", "offset": [686, 699]}, {"key": "responsible-for", "type": "clause", "offset": [714, 729]}, {"key": "providing-the", "type": "clause", "offset": [730, 743]}], "samples": [{"hash": "9YtSLYdsZ9n", "uri": "/contracts/9YtSLYdsZ9n#technology-sharing", "label": "Development, Licensing and Distribution Agreement (Resound Corp)", "score": 18.0, "published": true}, {"hash": "9Mw4VKfFTIn", "uri": "/contracts/9Mw4VKfFTIn#technology-sharing", "label": "Development, Licensing and Distribution Agreement (Resound Corp)", "score": 18.0, "published": true}], "hash": "70b46c66eaab1b0ba433e4b708a29b6f", "id": 1}, {"size": 2, "snippet": "Upon the Galderma Start Date, and thereafter at least [***] or more frequently upon Galderma\u2019s request, Sol-Gel shall provide to Galderma all data and documents Controlled by any Sol-Gel Entities and related to the Licensed Product that are reasonably necessary or useful for Galderma to Commercialize and perform Medical Affairs with respect to Licensed Product in the Territory or to perform its obligations under Section 4.02 (Galderma Regulatory Responsibility), including Licensed Know-How, regulatory data, and clinical data. Throughout the Term, Sol-Gel shall provide Galderma with updates of any material regulatory developments (e.g., NDA or NDS filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Sol-Gel, or Sol-Gel\u2019s Affiliates or licensees. In addition, at least [***] or more frequently upon Galderma\u2019s request, Sol-Gel shall make available to Galderma copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case, that are related to Licensed Product in the Field and Controlled by the Sol-Gel Entities or any of their licensees or sublicensees (collectively, the \u201cSol-Gel Product Data\u201d), to the extent (i) such Sol-Gel Product Data are necessary or reasonably useful for any Galderma Entity to Commercialize or perform Medical Affairs with respect to Licensed Product in the Field in the Territory in accordance with this Agreement, or (ii) such Sol-Gel Product Data are required by Regulatory Authority in the Territory in connection with the Commercialization of or performance of Medical Affairs with respect to Licensed Product in the Field in the Territory.", "snippet_links": [{"key": "start-date", "type": "definition", "offset": [18, 28]}, {"key": "related-to", "type": "clause", "offset": [200, 210]}, {"key": "licensed-product", "type": "clause", "offset": [215, 231]}, {"key": "reasonably-necessary", "type": "clause", "offset": [241, 261]}, {"key": "to-commercialize", "type": "definition", "offset": [285, 301]}, {"key": "medical-affairs", "type": "clause", "offset": [314, 329]}, {"key": "with-respect-to", "type": "clause", "offset": [330, 345]}, {"key": "in-the-territory", "type": "clause", "offset": [363, 379]}, {"key": "regulatory-responsibility", "type": "definition", "offset": [439, 464]}, {"key": "licensed-know", "type": "definition", "offset": [477, 490]}, {"key": "regulatory-data", "type": "clause", "offset": [496, 511]}, {"key": "clinical-data", "type": "definition", "offset": [517, 530]}, {"key": "the-term", "type": "clause", "offset": [543, 551]}, {"key": "regulatory-developments", "type": "clause", "offset": [613, 636]}, {"key": "regulatory-approval", "type": "definition", "offset": [701, 720]}, {"key": "relating-to", "type": "definition", "offset": [722, 733]}, {"key": "in-addition", "type": "clause", "offset": [808, 819]}, {"key": "available-to", "type": "definition", "offset": [899, 911]}, {"key": "copies-of", "type": "definition", "offset": [921, 930]}, {"key": "regulatory-documents", "type": "definition", "offset": [931, 951]}, {"key": "safety-and", "type": "clause", "offset": [998, 1008]}, {"key": "pharmacovigilance-data", "type": "definition", "offset": [1009, 1031]}, {"key": "each-case", "type": "definition", "offset": [1036, 1045]}, {"key": "in-the-field", "type": "clause", "offset": [1084, 1096]}, {"key": "product-data", "type": "definition", "offset": [1206, 1218]}, {"key": "to-the-extent", "type": "clause", "offset": [1222, 1235]}, {"key": "in-accordance-with", "type": "definition", "offset": [1432, 1450]}, {"key": "this-agreement", "type": "clause", "offset": [1451, 1465]}, {"key": "required-by-regulatory-authority", "type": "clause", "offset": [1505, 1537]}, {"key": "in-connection-with", "type": "clause", "offset": [1555, 1573]}], "samples": [{"hash": "l4ru099Bca3", "uri": "/contracts/l4ru099Bca3#technology-sharing", "label": "License Agreement (Sol-Gel Technologies Ltd.)", "score": 33.2546201232, "published": true}, {"hash": "iUEbjglO9Nu", "uri": "/contracts/iUEbjglO9Nu#technology-sharing", "label": "License Agreement (Sol-Gel Technologies Ltd.)", "score": 33.2546201232, "published": true}], "hash": "271b2682c8e8a20f5c3a454b281e973d", "id": 2}, {"size": 2, "snippet": "Sovello will agree to share certain technology advancements (namely: [****]) as implemented in production by the closing date of this agreement. Evergreen will acquire full rights to make, use, have made, sublicense, etc., these technology advancements without royalty payments in perpetuity. Once Sovello has provided the above listed technology advancements, Evergreen will acknowledge the completion of this Technology Sharing in writing. Draft Term Sheet String Ribbon License Agreement Evergreen \u2014 Exhibit A We agree to this non-binding overview of principals as basis for a new license agreement between Evergreen and Sovello replacing the existing QLA and LTTA unless otherwise stated. Thalheim, 18-3-2010 Marlboro, March 3, 2010 /s/ \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 /s/ \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587. \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Sovello AG Evergreen Solar Inc. Loan Agreement dated April 30, 2007 incl. amendments dated May 22, 2007 and September 1, 2008 Tranche A 37.500.000,00 -10.220.261,31 27.279.738,69 69.836,13 Tranche B **) 5.786.306,29 -3.841.436,42 1.944.869,87 4.978,87 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587 \u2587,\u2587\u2587 \u2587,\u2587\u2587 \u2587,\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587 25.000.000,00 -6.813.507,54 18.186.492,46 46.557,42 Interest rate swap ***) 318.209,10 Total 68.286.306,29 -20.875.205,27 47.411.101,02 439.581,52 *) According to bank confirmation Shareholders\u2019 payments were used for loan redemptions (EUR 20.875.205,27) and interest payments (EUR 509.696,76). **) Regarding Tranche B Q-Cells SE and REC ASA have made a payment as security for Evergreen (EUR 1.942.451,02). Therefore, Tranche B was not yet formally reduced. ***) The interest rate swap is a fixed-for-floating rate swap and refers to Tranche A. The swap was terminated by the Syndicated Banks together with the Loan Agreement in January 2010. ****) Interest incurred until closing date must be calculated at closing. TOTAL Sales Revenue K EUR 219.297 111.731 10.293 12.342 20.750 19.584 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] TOTAL COGS K EUR 167.242 127.318 10.789 14.545 19.838 18.694 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] GROSS PROFIT K EUR 52.054 -15.588 -496 -2.203 912 890 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Gross Margin % 23,7 % -14,0 % -4.8 % -17.8 % 4.4 % 4.5 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] General & Administrative Expense*) K EUR 9.846 9.489 653 726 819 819 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Selling expenses K EUR 5.886 4.078 246 363 509 513 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] R&D Expenses K EUR 1.401 3.705 322 299 640 640 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Projekt Cost SV3 K EUR 4.309 14.226 0 0 0 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Total operating expenses K EUR 21.442 31.499 1.221 1.388 1.968 1.973 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] EBIT K EUR 30.612 -47.087 -1.717 -3.591 -1.056 -1.083 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] EBIT Ratio % 14,0 % -42,1 % -16.7 % -29.1 % -5.1 % -5.5 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Financial result K EUR 8.865 16.104 2.152 1.890 1.146 415 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] EBT K EUR 21.747 -63.191 -3.870 -5.480 -2.202 -1.497 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Income Tax expenses (23%) K EUR 4.363 -312 -98 -33 0 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Income K EUR 17.384 -62.879 -3.772 -5.447 -2.202 -1.497 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Income Ratio 8 % -56 % -37 % -44 % -11 % -8 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] EBITDA K EUR 46.427 -24.368 830 -1.026 1.618 1.855 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] EBITDA Ratio % 21,2 % -21,8 % 8,1 % -8,3 % 7.8 % 9.5 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Production Volume KWp 84.874 58.261 8.814 7.952 9.847 11.620 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Sales Volume KWp 81.591 57.139 6.111 7.104 12.500 12.800 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Sales price EUR/Wp 2,61 1,92 1,68 1,68 1,68 1,53 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Total COGS EUR/Wp 2,05 2,23 1,77 2,05 1,59 1,46 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Total OpExpenses EUR/Wp 0,26 0,55 0,20 0,20 0,16 0,15 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Factory yield (running lines) % 73,94 % 71,07 % 71,8 % 73,9 % 72.0 % 77.3 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Cell efficiency (running lines) % 14,86 % 15,07 % 15,3 % 15,3 % 15.3 % 15.4 % [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] thereof restricted 2.778 4.061 3.821 3.821 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Accounts receivable net of Factoring 48.858 10.320 13.868 14.035 28.210 32.081 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Grants receivable 37.731 14.027 14.061 14.120 14.355 14.555 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Inventories 32.219 35.574 40.369 41.530 38.309 36.539 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Other assets 19.138 5.081 2.672 4.775 4.775 3.075 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Account payable 26.744 20.423 19.682 19.075 22.066 21.585 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Interest liability shareholders \u2014 9.368 10.234 11.084 11.898 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Bank loan grants SV1+2 27.500 \u2014 \u2014 \u2014 \u2014 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Bank loan grants SV 3 6.000 5.786 5.786 1.945 1.945 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] ST borrowings \u2014 banks \u2014 \u2014 \u2014 \u2014 \u2014 15.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] IB loan \u2014 \u2014 \u2014 \u2014 10.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Accrued warranty 1.960 1.985 2.020 2.043 2.198 2.345 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Accruals & Other liabilities 17.425 23.378 24.187 25.423 25.479 9.641 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Grants Special item 66.026 63.317 63.351 63.410 63.645 63.845 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Grants amortization (12.568 ) (16.525 ) (17.123 ) (17.745 ) (18.307 ) (18.893 ) [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - shareholder SV1/2 90.000 90.000 90.000 90.000 90.000 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - banks SV1/2 52.500 37.500 \u2014 \u2014 \u2014 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - shareholder SV3 36.762 35.084 35.917 36.354 36.354 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - banks SV3 35.000 25.000 62.500 45.466 45.466 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - shareholder Bridge \u2014 15.000 15.000 15.000 15.000 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] LT borrowings - shareholder WC 12.000 24.000 24.000 24.000 24.000 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Common stock 480 480 480 480 480 480 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] APIC \u2014 common stock + OCI 90.627 109.127 109.127 130.512 130.512 358.879 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] OCI (883 ) (330 ) (336 ) \u2014 \u2014 \u2014 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Retained Earnings 188 17.572 (45.306 ) (49.078 ) (54.525 ) (56.726 ) [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Income 17.384 (62.879 ) (3.772 ) (5.447 ) (2.202 ) (1.497 ) [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Income IFRS 17.384 -62.879 -3.772 -5.447 -2.202 -1.497 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Depreciation 22.376 29.618 3.145 3.186 3.236 3.523 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Amortization Grants -6.564 -6.900 -598 -622 -562 -586 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Non-Cash items 1.342 14.756 1.733 1.383 0 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Amortization/Change prepayment Silicon 0 16.061 2.565 104 337 363 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Inventories -10.125 -3.355 -4.795 -1.161 3.221 1.770 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Accounts Receivable & other assets -26.676 45.491 -1.172 -2.329 -14.410 -2.372 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Accounts payable & other liabilities 16.752 1.611 1.054 1.495 3.402 -2.684 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Cash provided by Operating Activities 14.488,9 34.403 -1.840 -3.391 -6.978 -1.483 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Grants received 0 30.566 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Grant repayments (incl. Interest) 0 0 0 0 -11.693 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Change investment liability -8.293 -957 -545 850 -1.594 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Capital Spendings (additions fixed asset schedule) -104.714 -37.818 -481 -1.206 -2.350 -4.509 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Silicon Prepayment 7.090 1.226 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Cash used for Investing Activities -97.624 -14.319 -1.438 -1.751 -1.500 -17.797 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Waiver Borrowing SH SV1 & SV2 0 0 0 0 0 -90.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Borrowing banks SV1 & SV2 -30.000 -15.000 0 0 0 0 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Waiver Borrowing SH SV3 34.817 15.026 0 0 0 -63.252 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Waiver Borrowing SH W/C 12.005 11.996 0 0 0 -24.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Borrowing banks Tranche A/D 35.000 -10.000 0 -17.034 0 -45.466 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Financing fees -724 0 [****] [****] [****] [****] [****] [****] [****] Bridge Financing Grants / Tranche B 6.000 -27.714 0 -3.841 0 -1.945 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Bank loan (remaining 15 MIO \u20ac) 0 0 0 0 0 15.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] IB loan 0 0 0 0 10.000 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Seller\u2019s Cash Contribution (Equity) 18.500 0 21.385 0 11.115 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Purchaser\u2019s Cash Contribution (Equity) 40.000 [****] [****] [****] [****] [****] Financing fees / IPO Proceeds (net) -150 0 [****] [****] [****] [****] [****] Net Cash provided by Financing Activities 57.098 -7.342 0 510 0 28.704 [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Net Increase (Decrease) in Cash & Equivalents -26.037 12.742 -3.278 -4.632 -8.478 9.425 [****] [****", "snippet_links": [{"key": "technology-advancements", "type": "clause", "offset": [36, 59]}, {"key": "date-of-this-agreement", "type": "definition", "offset": [121, 143]}, {"key": "full-rights", "type": "clause", "offset": [168, 179]}, {"key": "in-perpetuity", "type": "clause", "offset": [278, 291]}, {"key": "completion-of", "type": "clause", "offset": [392, 405]}, {"key": "in-writing", "type": "clause", "offset": [430, 440]}, {"key": "term-sheet", "type": "clause", "offset": [448, 458]}, {"key": "exhibit-a", "type": "clause", "offset": [503, 512]}, {"key": "we-agree-to", "type": "clause", "offset": [513, 524]}, {"key": "agreement-between", "type": "clause", "offset": [592, 609]}, {"key": "unless-otherwise-stated", "type": "clause", "offset": [668, 691]}, {"key": "tranche-a", "type": "definition", "offset": [908, 917]}, {"key": "tranche-b", "type": "definition", "offset": [971, 980]}, {"key": "interest-rate-swap", "type": "definition", "offset": [1121, 1139]}, {"key": "bank-confirmation", "type": "definition", "offset": [1232, 1249]}, {"key": "interest-payments", "type": "definition", "offset": [1328, 1345]}, {"key": "the-interest-rate", "type": "clause", "offset": [1533, 1550]}, {"key": "a-fixed", "type": "clause", "offset": [1559, 1566]}, {"key": "floating-rate", "type": "definition", "offset": [1571, 1584]}, {"key": "the-swap", "type": "clause", "offset": [1615, 1623]}, {"key": "the-loan-agreement", "type": "clause", "offset": [1677, 1695]}, {"key": "interest-incurred", "type": "definition", "offset": [1719, 1736]}, {"key": "until-closing", "type": "clause", "offset": [1737, 1750]}, {"key": "at-closing", "type": "clause", "offset": [1775, 1785]}, {"key": "sales-revenue", "type": "definition", "offset": [1793, 1806]}, {"key": "gross-profit", "type": "definition", "offset": [2184, 2196]}, {"key": "gross-margin", "type": "definition", "offset": [2371, 2383]}, {"key": "administrative-expense", "type": "definition", "offset": [2571, 2593]}, {"key": "selling-expenses", "type": "clause", "offset": [2763, 2779]}, {"key": "rd-expenses", "type": "definition", "offset": [2947, 2959]}, {"key": "total-operating-expenses", "type": "definition", "offset": [3304, 3328]}, {"key": "ebit-ratio", "type": "clause", "offset": [3693, 3703]}, {"key": "income-tax-expenses", "type": "definition", "offset": [4261, 4280]}, {"key": "net-income", "type": "clause", "offset": [4414, 4424]}, {"key": "ebitda-ratio", "type": "clause", "offset": [4974, 4986]}, {"key": "production-volume", "type": "clause", "offset": [5162, 5179]}, {"key": "sales-volume", "type": "definition", "offset": [5356, 5368]}, {"key": "sales-price", "type": "clause", "offset": [5546, 5557]}, {"key": "accounts-receivable", "type": "clause", "offset": [6694, 6713]}, {"key": "other-assets", "type": "definition", "offset": [7286, 7298]}, {"key": "bank-loan", "type": "definition", "offset": [7856, 7865]}, {"key": "other-liabilities", "type": "definition", "offset": [8741, 8758]}, {"key": "special-item", "type": "definition", "offset": [8940, 8952]}, {"key": "common-stock", "type": "clause", "offset": [10527, 10539]}, {"key": "retained-earnings", "type": "definition", "offset": [11067, 11084]}, {"key": "cash-items", "type": "definition", "offset": [12033, 12043]}, {"key": "accounts-payable", "type": "definition", "offset": [12803, 12819]}, {"key": "net-cash-provided-by-operating-activities", "type": "definition", "offset": [13011, 13052]}, {"key": "investment-liability", "type": "definition", "offset": [13496, 13516]}, {"key": "asset-schedule", "type": "definition", "offset": [13671, 13685]}, {"key": "investing-activities", "type": "clause", "offset": [13989, 14009]}, {"key": "financing-fees", "type": "definition", "offset": [15118, 15132]}, {"key": "bridge-financing", "type": "clause", "offset": [15189, 15205]}, {"key": "cash-contribution", "type": "clause", "offset": [15736, 15753]}, {"key": "ipo-proceeds", "type": "clause", "offset": [16019, 16031]}, {"key": "financing-activities", "type": "definition", "offset": [16101, 16121]}, {"key": "net-increase", "type": "definition", "offset": [16284, 16296]}, {"key": "in-cash", "type": "definition", "offset": [16308, 16315]}], "samples": [{"hash": "drOLnHrweZV", "uri": "/contracts/drOLnHrweZV#technology-sharing", "label": "Share Purchase Agreement (Evergreen Solar Inc)", "score": 19.7008898015, "published": true}], "hash": "6853fed6053a6ec3bb61b177bdbacc63", "id": 4}, {"size": 2, "snippet": "6.1 Notwithstanding the use of the term \u2018Technology Sharing\u2019 and notwithstanding anything contained in this Agreement or any of the Related Agreements to the contrary, nothing in any of the Transaction Documents is intended to or is to be interpreted as an obligation of Kamada to transfer legal title to any of the intellectual property assets licensed by Kamada under this Agreement to \u2587\u2587\u2587\u2587\u2587\u2587. Further, for the avoidance of doubt, the term \u2018Technology Sharing Plan\u2019 (and its related defined terms) is intended to refer to the process by which Kamada will disclose to \u2587\u2587\u2587\u2587\u2587\u2587 and will train \u2587\u2587\u2587\u2587\u2587\u2587 with respect to the skills, knowledge, technologies and methods of manufacturing that Kamada possesses (or will develop during the Term) to ensure that \u2587\u2587\u2587\u2587\u2587\u2587 is able to exploit such skills, knowledge, technologies and methods in the \u2587\u2587\u2587\u2587\u2587\u2587 Territory as more specifically detailed in Exhibit 1.67 to this Agreement.\n6.2 Kamada expressly undertakes, under the provisions set forth below and as further set forth in the Technology Sharing Plan (Exhibit \u200e1.67) the following:\n(a) by [*****], for no additional consideration, to complete a speedy and efficient disclosure to \u2587\u2587\u2587\u2587\u2587\u2587 of all Technology Sharing Documentation, including, without limitation, Regulatory Documentation, all documentation related to yield improvement for A1PI, and all other information, materials and documentation reasonably necessary for or directly related to \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 exercise of the rights licensed herein as listed in Exhibit \u200e1.39, as well as all copies of documents reasonably requested by \u2587\u2587\u2587\u2587\u2587\u2587, provided that such documents are in Kamada\u2019s possession and that such access shall comply with all state and federal statute requirements;\n(b) until the end of the Technology Sharing Term, to provide \u2587\u2587\u2587\u2587\u2587\u2587 and relevant health authorities with such access to Kamada\u2019s offices and laboratory and production facilities in Israel as is reasonable to advance the sharing of Kamada\u2019s technology under the Technology Sharing Plan, upon prior coordination with Kamada of at least [*****] and during normal business hours, provided that such visits may not unduly burden Kamada\u2019s normal work activities, and to provide consultation and advice reasonably requested by \u2587\u2587\u2587\u2587\u2587\u2587 or any said authority during any such visit, all for no additional consideration;\n(c) for [*****], to provide \u2587\u2587\u2587\u2587\u2587\u2587 and \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 third party contract partners with all other consultation and advice necessary or evidently beneficial for effecting said disclosure, including training and consultation performed at such locations as determined in the Technology Sharing Plan, with Kamada providing up to an aggregate amount of [*****] for no additional consideration to fulfill its obligations under the Technology Sharing Plan. For clarity, the [*****] shall include all time spent by Kamada personnel or its outside advisors in fulfilling its obligations under the Technology Sharing Plan unless otherwise specifically indicated under the Technology Sharing Plan. [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.\n(d) until the end of the Technology Sharing Term, to supply \u2587\u2587\u2587\u2587\u2587\u2587, for no additional consideration, with quantities of the Biologic Material as listed in Exhibit \u200e1.39 necessary or beneficial for \u2587\u2587\u2587\u2587\u2587\u2587 to start development of the manufacturing of \u2587\u2587\u2587\u2587\u2587\u2587 Products and to establish production of the \u2587\u2587\u2587\u2587\u2587\u2587 Products at its own facilities provided that such biological material is in Kamada's possession and that \u2587\u2587\u2587\u2587\u2587\u2587 bears all costs associated with shipping the Biologic Material; and,\n(e) until the end of the Technology Sharing Term, ensure that, throughout the disclosure process it shall have adequate numbers of persons qualified to provide the foregoing assistance and services to \u2587\u2587\u2587\u2587\u2587\u2587.\n6.3 Notwithstanding the dates and timelines set forth in this Agreement and in Exhibit \u200e1.67, the Parties acknowledge and agree that the timelines and dates shall be accelerated pursuant to the Distribution Agreement in the event of a Failure (as such term is defined therein). The Parties further agree that time is of the essence as regards all said actions, and in particular the disclosure of Kamada Licensed Know-How, technology, Biological Material, Technology Sharing Documentation and other information and materials to \u2587\u2587\u2587\u2587\u2587\u2587.\n6.4 Kamada shall use its Commercially Reasonable Efforts to complete the timely disclosure to \u2587\u2587\u2587\u2587\u2587\u2587 of all Technology Sharing Documentation, Kamada Licensed Know-How, Biological Material, Regulatory Documentation, and other documentation and materials as set forth in Sections \u200e6.2(a) and \u200e6.2(d), except that if any delay in such disclosure is the result of a delay by \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 obligation to disclose shall be delayed by such period of time reasonably resulting from \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 delay, but no less than the period of \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 delay.\n6.5 If \u2587\u2587\u2587\u2587\u2587\u2587 requires additional Kamada resource time or requires consultancy and advice after using the [*****] personnel hours, which are for no additional consideration, or after [*****] from the Effective Date, the Parties may mutually agree on reasonable support. Whenever support including support provided under Section \u200e6.2(c) requires Kamada personnel to travel to \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 facilities or any other facility determined by \u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587\u2587\u2587\u2587\u2587 shall bear all reasonable travel expenses (including accommodation) and a per diem [*****] per day for meals. For additional support beyond the [*****] personnel hours under Section \u200e6.2(c) \u2587\u2587\u2587\u2587\u2587\u2587 shall pay the hourly fees of the Kamada employees traveling to \u2587\u2587\u2587\u2587\u2587\u2587 as follows: for [*****] per hour, for [*****] per hour, for [*****] per hour and [*****] (e.g., [*****] per hour. The hourly fees of other Kamada employees which are not described above, traveling to \u2587\u2587\u2587\u2587\u2587\u2587 shall be determined on a case-by-case basis. Following a \u2587\u2587\u2587\u2587\u2587\u2587 request for additional support Kamada will provide the estimated cost including hourly rates. During such support, Kamada will periodically provide \u2587\u2587\u2587\u2587\u2587\u2587 with a detailed report of the hours worked by such Kamada employees, the employees utilized, and the employee rates which are to be charged to \u2587\u2587\u2587\u2587\u2587\u2587. \u2587\u2587\u2587\u2587\u2587\u2587 shall pay all fees and expenses due to Kamada under this Section \u200e6.5 within [*****] days of its receipt of an invoice related thereto. [*****] Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission.\n6.6 Neither Party shall be obliged to disclose any information to the other if it is prevented from doing so by an obligation to another person, provided, however, that the Parties agree to make all reasonable efforts to obtain consent to disclose such information. If that obligation is not absolute but is conditional upon the observance of conditions there shall be no obligation to make such disclosure except against an undertaking to observe such conditions.\n6.7 If \u2587\u2587\u2587\u2587\u2587\u2587 finds information and data provided by Kamada incorrect or incomplete, \u2587\u2587\u2587\u2587\u2587\u2587 may request that Kamada provide additional information necessary to correct or supplement previous information, and Kamada shall provide such information and data without undue delay, provided that such information is within Kamada\u2019s possession.\n6.8 Kamada shall not at any time after the Effective Date destroy any relevant documents related to the A1PI technology, and in particular Kamada will not destroy or dispose of any documents related to the clinical investigation of the A1PI and A1PI containing products without notice to \u2587\u2587\u2587\u2587\u2587\u2587. If \u2587\u2587\u2587\u2587\u2587\u2587 desires to dispose of any such document, Kamada shall inform \u2587\u2587\u2587\u2587\u2587\u2587 of such desire to dispose of such documents, and shall, at \u2587\u2587\u2587\u2587\u2587\u2587\u2019\u2587 option, disclose any such document to \u2587\u2587\u2587\u2587\u2587\u2587 without undue delay.", "snippet_links": [{"key": "notwithstanding-the", "type": "definition", "offset": [4, 23]}, {"key": "use-of-the-term", "type": "clause", "offset": [24, 39]}, {"key": "agreement-or", "type": "definition", "offset": [108, 120]}, {"key": "related-agreements", "type": "definition", "offset": [132, 150]}, {"key": "the-transaction-documents", "type": "clause", "offset": [186, 211]}, {"key": "to-transfer", "type": "clause", "offset": [278, 289]}, {"key": "title-to", "type": "clause", "offset": [296, 304]}, {"key": "intellectual-property-assets", "type": "clause", "offset": [316, 344]}, {"key": "agreement-to", "type": "definition", "offset": [375, 387]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [405, 431]}, {"key": "technology-sharing-plan", "type": "definition", "offset": [443, 466]}, {"key": "defined-terms", "type": "definition", "offset": [485, 498]}, {"key": "the-process", "type": "clause", "offset": [524, 535]}, {"key": "with-respect-to", "type": "clause", "offset": [598, 613]}, {"key": "during-the-term", "type": "clause", "offset": [718, 733]}, {"key": "to-ensure", "type": "clause", "offset": [735, 744]}, {"key": "that-\u2587", "type": "clause", "offset": [745, 751]}, {"key": "the-\u2587", "type": "clause", "offset": [828, 833]}, {"key": "more-specifically", "type": "clause", "offset": [852, 869]}, {"key": "to-this-agreement", "type": "clause", "offset": [895, 912]}, {"key": "the-provisions", "type": "clause", "offset": [953, 967]}, {"key": "the-technology", "type": "clause", "offset": [1012, 1026]}, {"key": "no-additional-consideration", "type": "clause", "offset": [1091, 1118]}, {"key": "without-limitation", "type": "clause", "offset": [1228, 1246]}, {"key": "regulatory-documentation", "type": "definition", "offset": [1248, 1272]}, {"key": "yield-improvement", "type": "clause", "offset": [1303, 1320]}, {"key": "materials-and-documentation", "type": "clause", "offset": [1358, 1385]}, {"key": "necessary-for", "type": "definition", "offset": [1397, 1410]}, {"key": "directly-related-to", "type": "definition", "offset": [1414, 1433]}, {"key": "rights-licensed", "type": "clause", "offset": [1459, 1474]}, {"key": "copies-of-documents", "type": "clause", "offset": [1525, 1544]}, {"key": "requested-by", "type": "definition", "offset": [1556, 1568]}, {"key": "provided-that", "type": "clause", "offset": [1577, 1590]}, {"key": "comply-with", "type": "clause", "offset": [1660, 1671]}, {"key": "state-and-federal", "type": "definition", "offset": [1676, 1693]}, {"key": "to-provide", "type": "definition", "offset": [1766, 1776]}, {"key": "health-authorities", "type": "definition", "offset": [1797, 1815]}, {"key": "access-to", "type": "definition", "offset": [1826, 1835]}, {"key": "production-facilities", "type": "clause", "offset": [1872, 1893]}, {"key": "to-advance", "type": "definition", "offset": [1921, 1931]}, {"key": "normal-business-hours", "type": "definition", "offset": [2069, 2090]}, {"key": "work-activities", "type": "definition", "offset": [2156, 2171]}, {"key": "consultation-and-advice", "type": "clause", "offset": [2188, 2211]}, {"key": "third-party-contract", "type": "clause", "offset": [2373, 2393]}, {"key": "other-consultation", "type": "clause", "offset": [2412, 2430]}, {"key": "training-and-consultation", "type": "clause", "offset": [2517, 2542]}, {"key": "aggregate-amount", "type": "definition", "offset": [2648, 2664]}, {"key": "obligations-under-the", "type": "clause", "offset": [2723, 2744]}, {"key": "for-clarity", "type": "clause", "offset": [2770, 2781]}, {"key": "time-spent-by", "type": "clause", "offset": [2813, 2826]}, {"key": "outside-advisors", "type": "clause", "offset": [2851, 2867]}, {"key": "been-redacted", "type": "clause", "offset": [3059, 3072]}, {"key": "filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [3077, 3137]}, {"key": "for-\u2587", "type": "clause", "offset": [3332, 3337]}, {"key": "development-of-the", "type": "clause", "offset": [3352, 3370]}, {"key": "to-establish", "type": "clause", "offset": [3408, 3420]}, {"key": "facilities-provided", "type": "clause", "offset": [3466, 3485]}, {"key": "biological-material", "type": "definition", "offset": [3496, 3515]}, {"key": "all-costs", "type": "definition", "offset": [3564, 3573]}, {"key": "associated-with", "type": "definition", "offset": [3574, 3589]}, {"key": "disclosure-process", "type": "clause", "offset": [3705, 3723]}, {"key": "the-foregoing", "type": "definition", "offset": [3787, 3800]}, {"key": "dates-and-timelines", "type": "clause", "offset": [3860, 3879]}, {"key": "the-parties-acknowledge-and-agree-that", "type": "clause", "offset": [3930, 3968]}, {"key": "the-distribution-agreement", "type": "clause", "offset": [4026, 4052]}, {"key": "in-the-event-of-a", "type": "clause", "offset": [4053, 4070]}, {"key": "the-parties-further-agree", "type": "clause", "offset": [4114, 4139]}, {"key": "time-is-of-the-essence", "type": "clause", "offset": [4145, 4167]}, {"key": "in-particular", "type": "clause", "offset": [4201, 4214]}, {"key": "disclosure-of", "type": "clause", "offset": [4219, 4232]}, {"key": "licensed-know", "type": "definition", "offset": [4240, 4253]}, {"key": "information-and-materials", "type": "clause", "offset": [4335, 4360]}, {"key": "complete-the", "type": "clause", "offset": [4432, 4444]}, {"key": "timely-disclosure", "type": "clause", "offset": [4445, 4462]}, {"key": "other-documentation", "type": "definition", "offset": [4591, 4610]}, {"key": "obligation-to-disclose", "type": "clause", "offset": [4760, 4782]}, {"key": "period-of-time", "type": "clause", "offset": [4808, 4822]}, {"key": "resulting-from", "type": "definition", "offset": [4834, 4848]}, {"key": "the-period", "type": "clause", "offset": [4882, 4892]}, {"key": "from-the-effective-date", "type": "clause", "offset": [5103, 5126]}, {"key": "mutually-agree", "type": "definition", "offset": [5144, 5158]}, {"key": "support-provided", "type": "clause", "offset": [5209, 5225]}, {"key": "other-facility", "type": "definition", "offset": [5314, 5328]}, {"key": "travel-expenses", "type": "definition", "offset": [5384, 5399]}, {"key": "per-diem", "type": "definition", "offset": [5432, 5440]}, {"key": "per-day", "type": "definition", "offset": [5449, 5456]}, {"key": "additional-support", "type": "clause", "offset": [5472, 5490]}, {"key": "hourly-fees", "type": "clause", "offset": [5569, 5580]}, {"key": "a-\u2587", "type": "clause", "offset": [5887, 5890]}, {"key": "request-for-additional", "type": "clause", "offset": [5896, 5918]}, {"key": "will-provide", "type": "clause", "offset": [5934, 5946]}, {"key": "estimated-cost", "type": "definition", "offset": [5951, 5965]}, {"key": "hourly-rates", "type": "definition", "offset": [5976, 5988]}, {"key": "report-of-the", "type": "clause", "offset": [6067, 6080]}, {"key": "hours-worked", "type": "definition", "offset": [6081, 6093]}, {"key": "the-employees", "type": "clause", "offset": [6120, 6133]}, {"key": "fees-and-expenses", "type": "definition", "offset": [6223, 6240]}, {"key": "receipt-of-an-invoice", "type": "definition", "offset": [6306, 6327]}, {"key": "neither-party-shall", "type": "clause", "offset": [6481, 6500]}, {"key": "another-person", "type": "clause", "offset": [6606, 6620]}, {"key": "agree-to", "type": "clause", "offset": [6658, 6666]}, {"key": "efforts-to-obtain", "type": "clause", "offset": [6687, 6704]}, {"key": "consent-to-disclose", "type": "clause", "offset": [6705, 6724]}, {"key": "such-information", "type": "definition", "offset": [6725, 6741]}, {"key": "observance-of-conditions", "type": "clause", "offset": [6806, 6830]}, {"key": "no-obligation-to", "type": "clause", "offset": [6846, 6862]}, {"key": "data-provided", "type": "clause", "offset": [6978, 6991]}, {"key": "provide-additional-information", "type": "clause", "offset": [7058, 7088]}, {"key": "without-undue-delay", "type": "definition", "offset": [7197, 7216]}, {"key": "at-any-time", "type": "clause", "offset": [7301, 7312]}, {"key": "after-the-effective-date", "type": "clause", "offset": [7313, 7337]}, {"key": "relevant-documents", "type": "definition", "offset": [7350, 7368]}, {"key": "dispose-of", "type": "definition", "offset": [7446, 7456]}, {"key": "without-notice-to", "type": "clause", "offset": [7550, 7567]}], "samples": [{"hash": "jIWr7AgGhGI", "uri": "/contracts/jIWr7AgGhGI#technology-sharing", "label": "Technology License Agreement (Kamada LTD)", "score": 24.227926078, "published": true}], "hash": "af2a80e2a4d64b0d19bf9841ee53ca1a", "id": 5}, {"size": 1, "snippet": "(a) Verona shall provide to Nuance electronic copies of the documents relating to Licensed Products set forth on Exhibit B hereto promptly after the Effective Date but in any event within ninety (90) days of the Effective Date.\n(b) To the extent not included in Exhibit B, Verona shall also provide to Nuance all Verona Know-How, and all other additional data and documents existing as of the Effective Date that are Controlled by the Verona Entity and reasonably necessary for the Nuance Entity to Develop or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement, which Nuance did not and could not reasonably know of.\n(c) Throughout the Term, Verona shall provide Nuance with an update of any material regulatory developments (e.g., NDA filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by the Verona Entity, and upon Nuance\u2019s request, Verona shall make available to Nuance copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Verona Entity (collectively, the \u201cVerona Product Data\u201d), to the extent such Verona Product Data is reasonably necessary for any Nuance Entity to Develop or Commercialize Licensed Product in the Field in the Territory in accordance with this Agreement.\n(d) No provision of this Agreement shall require Verona to provide to Nuance any intellectual property or information (including Know-How, data, documents or files) licensed to, or provided to, Verona by Ligand UK Development Limited (formerly Vernalis Development Limited).\n(e) Throughout the Term, Verona shall provide reasonable technical assistance as reasonably requested by Nuance in support of the Development and Commercialization of the Licensed Product in the Field in the Territory, at Nuance\u2019s costs and expenses.", "snippet_links": [{"key": "the-documents", "type": "clause", "offset": [56, 69]}, {"key": "relating-to", "type": "definition", "offset": [70, 81]}, {"key": "licensed-products", "type": "clause", "offset": [82, 99]}, {"key": "exhibit-b", "type": "definition", "offset": [113, 122]}, {"key": "after-the-effective-date", "type": "clause", "offset": [139, 163]}, {"key": "to-the-extent", "type": "clause", "offset": [232, 245]}, {"key": "not-included", "type": "clause", "offset": [246, 258]}, {"key": "additional-data-and-documents", "type": "clause", "offset": [344, 373]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [383, 407]}, {"key": "necessary-for", "type": "definition", "offset": [464, 477]}, {"key": "to-develop", "type": "definition", "offset": [496, 506]}, {"key": "in-the-field", "type": "clause", "offset": [541, 553]}, {"key": "in-the-territory", "type": "clause", "offset": [554, 570]}, {"key": "in-accordance-with", "type": "definition", "offset": [571, 589]}, {"key": "this-agreement", "type": "clause", "offset": [590, 604]}, {"key": "the-term", "type": "clause", "offset": [676, 684]}, {"key": "regulatory-developments", "type": "clause", "offset": [745, 768]}, {"key": "regulatory-authority", "type": "definition", "offset": [801, 821]}, {"key": "regulatory-approval", "type": "definition", "offset": [826, 845]}, {"key": "available-to", "type": "definition", "offset": [950, 962]}, {"key": "regulatory-documents", "type": "definition", "offset": [980, 1000]}, {"key": "safety-and", "type": "clause", "offset": [1047, 1057]}, {"key": "pharmacovigilance-data", "type": "definition", "offset": [1058, 1080]}, {"key": "each-case", "type": "definition", "offset": [1085, 1094]}, {"key": "related-to", "type": "clause", "offset": [1104, 1114]}, {"key": "product-data", "type": "definition", "offset": [1208, 1220]}, {"key": "provision-of", "type": "clause", "offset": [1426, 1438]}, {"key": "to-provide", "type": "definition", "offset": [1475, 1485]}, {"key": "intellectual-property", "type": "definition", "offset": [1500, 1521]}, {"key": "technical-assistance", "type": "clause", "offset": [1751, 1771]}, {"key": "by-nuance", "type": "clause", "offset": [1796, 1805]}, {"key": "commercialization-of-the-licensed-product", "type": "clause", "offset": [1840, 1881]}, {"key": "costs-and-expenses", "type": "definition", "offset": [1925, 1943]}], "samples": [{"hash": "9Wr9NMwOlWa", "uri": "/contracts/9Wr9NMwOlWa#technology-sharing", "label": "Collaboration and License Agreement (Verona Pharma PLC)", "score": 32.5920602327, "published": true}], "hash": "0d568e7a5537ee532d8500bcb12f6a3e", "id": 6}, {"size": 1, "snippet": "Cooperate as required in making its ------------------ technology available to the TeleCor division and assisting in the conversion of the Heartline system described below.", "snippet_links": [{"key": "as-required", "type": "clause", "offset": [10, 21]}, {"key": "available-to", "type": "definition", "offset": [66, 78]}, {"key": "conversion-of", "type": "clause", "offset": [121, 134]}], "samples": [{"hash": "le4ZG8Y6G8V", "uri": "/contracts/le4ZG8Y6G8V#technology-sharing", "label": "Assignment of Exclusive Marketing Rights (Compumed Inc)", "score": 16.0, "published": true}], "hash": "d4c63cac2daffe67eed7d38cf5cc0a8c", "id": 7}, {"size": 1, "snippet": "Monsanto agrees that it will provide access to its pelargonic acid technology and the Agent agrees that it will provide access its ammonium nonanoate technology, including, but not limited to, access to formulations, know-how and registrations for use within GroundClear and Roundup branded products. If the Agent does not deliver a Convenience Termination Notice on January 15, 2021, the parties will enter into a broader technology sharing agreement on terms to be mutually agreed by the parties.", "snippet_links": [{"key": "access-to", "type": "definition", "offset": [37, 46]}, {"key": "the-agent-agrees", "type": "clause", "offset": [82, 98]}, {"key": "not-limited", "type": "clause", "offset": [177, 188]}, {"key": "branded-products", "type": "definition", "offset": [283, 299]}, {"key": "convenience-termination-notice", "type": "definition", "offset": [333, 363]}, {"key": "the-parties-will", "type": "clause", "offset": [385, 401]}, {"key": "terms-to", "type": "definition", "offset": [455, 463]}, {"key": "by-the-parties", "type": "clause", "offset": [483, 497]}], "samples": [{"hash": "3VoTD1y3QJm", "uri": "/contracts/3VoTD1y3QJm#technology-sharing", "label": "Exclusive Agency and Marketing Agreement (Scotts Miracle-Gro Co)", "score": 30.5770020534, "published": true}], "hash": "ee566d6d3c3ea1a54457d7367e7423be", "id": 8}, {"size": 1, "snippet": "The parties agree to disclose to the other during the term of this Agreement their respective technologies and capabilities, including but not limited to E-Cruiter's Helius Platform, in the context of joint exploration of licensing and cross-licensing opportunities of such technologies and capabilities on mutually beneficial terms.", "snippet_links": [{"key": "to-disclose", "type": "definition", "offset": [18, 29]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [43, 76]}, {"key": "not-limited", "type": "clause", "offset": [139, 150]}, {"key": "the-context", "type": "clause", "offset": [186, 197]}], "samples": [{"hash": "cw9YIP2R0jA", "uri": "/contracts/cw9YIP2R0jA#technology-sharing", "label": "Sales & Marketing Agreement (E Cruiter Com Inc)", "score": 18.0, "published": true}], "hash": "2f8f3345e2a02fac85f7994930c45940", "id": 9}, {"size": 1, "snippet": "(a) Sol-Gel shall provide to SLP all data and documents Controlled by the Sol-Gel Entities and related to the Licensed Product that are reasonably necessary for SLP to Commercialize Licensed Product in the Territory, including Licensed Know-How, regulatory data, and clinical data. Throughout the Term, Sol-Gel shall provide SLP with an update of any material regulatory developments (e.g., NDA or NDS filed, meetings with Regulatory Authority, or Regulatory Approval) relating to a Licensed Product made by Sol-Gel, or Sol-Gel\u2019s Affiliates or licensees, and upon SLP\u2019s request, Sol-Gel shall make available to SLP copies of Regulatory Documents, clinical and preclinical data, and efficacy, safety and pharmacovigilance data, in each case that are related to Licensed Product in the Field and Controlled by the Sol-Gel Entities or any of their licensees (collectively, the \u201cSol-Gel Product Data\u201d), to the extent (i) such Sol-Gel Product Data are reasonably necessary for any SLP Entity to Commercialize the Licensed Product in the Field in the Territory in accordance with this Agreement and are Controlled by the Sol-Gel Entities,", "snippet_links": [{"key": "related-to", "type": "clause", "offset": [95, 105]}, {"key": "licensed-product", "type": "clause", "offset": [110, 126]}, {"key": "necessary-for", "type": "definition", "offset": [147, 160]}, {"key": "to-commercialize", "type": "definition", "offset": [165, 181]}, {"key": "in-the-territory", "type": "clause", "offset": [199, 215]}, {"key": "licensed-know", "type": "definition", "offset": [227, 240]}, {"key": "regulatory-data", "type": "clause", "offset": [246, 261]}, {"key": "clinical-data", "type": "definition", "offset": [267, 280]}, {"key": "the-term", "type": "clause", "offset": [293, 301]}, {"key": "regulatory-developments", "type": "clause", "offset": [360, 383]}, {"key": "regulatory-authority", "type": "definition", "offset": [423, 443]}, {"key": "regulatory-approval", "type": "definition", "offset": [448, 467]}, {"key": "relating-to", "type": "definition", "offset": [469, 480]}, {"key": "available-to", "type": "definition", "offset": [598, 610]}, {"key": "copies-of", "type": "definition", "offset": [615, 624]}, {"key": "regulatory-documents", "type": "definition", "offset": [625, 645]}, {"key": "safety-and", "type": "clause", "offset": [692, 702]}, {"key": "pharmacovigilance-data", "type": "definition", "offset": [703, 725]}, {"key": "each-case", "type": "definition", "offset": [730, 739]}, {"key": "in-the-field", "type": "clause", "offset": [777, 789]}, {"key": "product-data", "type": "definition", "offset": [883, 895]}, {"key": "to-the-extent", "type": "clause", "offset": [899, 912]}, {"key": "slp-entity", "type": "definition", "offset": [976, 986]}, {"key": "in-accordance-with", "type": "definition", "offset": [1055, 1073]}, {"key": "this-agreement", "type": "clause", "offset": [1074, 1088]}], "samples": [{"hash": "1Ig1ISqhqWc", "uri": "/contracts/1Ig1ISqhqWc#technology-sharing", "label": "License Agreement (Sol-Gel Technologies Ltd.)", "score": 35.1957563313, "published": true}], "hash": "856ff49f483e930311c87c7803adf3e6", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Iht0ZWNobm9sb2d5LXNoYXJpbmcjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 16, "title": "Technology Sharing", "parents": [["whereas", "WHEREAS"], ["governing-law-jurisdiction-service-of-process", "Governing Law Jurisdiction Service of Process"], ["service-of-process", "Service of Process"], ["development-of-product", "Development of Product"], ["regulatory-technology-sharing", "Regulatory Technology Sharing"]], "children": [["further", "Further"], ["sol-gel-regulatory-responsibility", "Sol-Gel Regulatory Responsibility"], ["technology-sharing", "Technology Sharing"], ["generic-products", "Generic Products"], ["galderma-product-data", "Galderma Product Data"]], "id": "technology-sharing", "related": [["technology", "Technology", "Technology"], ["technology-license", "Technology License", "Technology License"], ["computer-software", "Computer Software", "Computer Software"], ["new-technology", "New Technology", "New Technology"], ["computer-systems", "Computer Systems", "Computer Systems"]], "related_snippets": [], "updated": "2025-07-07T12:37:39+00:00", "also_ask": ["What safeguards ensure proprietary technology is not misused or disclosed?", "How can the clause be structured to allow for future technological developments?", "What are the most effective remedies for breach of technology sharing obligations?", "How does this clause compare to standard technology licensing provisions?", "What factors most influence a court\u2019s decision to enforce or limit technology sharing terms?"], "drafting_tip": "Specify the technologies covered to prevent disputes, define permitted uses to protect proprietary interests, and outline confidentiality obligations to safeguard sensitive information.", "explanation": "The Technology Sharing clause establishes the terms under which parties agree to share technological resources, such as software, patents, or proprietary know-how, during the course of their collaboration. Typically, this clause outlines what specific technologies are included, the permitted uses by each party, and any restrictions or obligations regarding confidentiality and intellectual property rights. Its core function is to facilitate cooperation and innovation between parties while protecting each party\u2019s proprietary interests and ensuring that shared technology is used appropriately."}, "json": true, "cursor": ""}}